BioSpace News Archive

PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the appointment of Mark Mullikin as Chief Financial Officer.

Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III (Nasdaq: ARYA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol “NAUT” Nautilus Biotechnology is expected to receive $350 million in proceeds through the business combination, including a $200 million fully committed PIPE led by Perceptive Advisors and other top-tier healthcare investors

Q-State Biosciences , a technology-derived medicines company, today announced that it has achieved the primary program completion milestone in its research collaboration with Chamishi Therapeutics.

- Business combination transaction with FS Development Corp., a special purpose acquisition company sponsored by Foresite Capital, completed on February 5, 2021 – - Combined company renamed Gemini Therapeutics, Inc. – - Common stock commences trading today on the Nasdaq Global Market under ticker symbol “GMTX” –

FairJourney Biologics (FJB) and IONTAS, leaders in the discovery and optimization of antibodies, have today announced the launch of a new protein sciences division, Flow Eighteen38.

Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease to Dyne Therapeutics.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the Agencja Badań Medycznych, awarded a grant equivalent to $1.5 million USD to the Maria Sklodowska-Curie National Research Institute to fund a Phase 1B/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.

-Kantaro’s COVID-SeroKlir and COVID-SeroIndex are high-performing tests that detect the presence and precise level of neutralizing antibodies¹- -First and only quantitative COVID-19 antibody tests that do not require proprietary equipment-

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand development, today announced that they have completed the development and initiated the commercial launch of NGL COVID-19 Spike Protein Affinity Resin

Inovalon, a leading provider of cloud-based platforms empowering data-driven healthcare, announced an 8-year engagement with the AIDS Healthcare Foundation, the world’s largest provider of HIV/AIDS medical care.